We have detected an active ad-blocker. Please consider whitelisting this website, to support our efforts in bringing you content.

Temasek Seeks Buyer For Alvogen’s Eastern European Operations

If your're seeing this, our systems have detected an ad-blocker. Please consider whitelisting this website, to support our efforts in bringing you content.

Changes are a foot in the cancer drug market.

 

 

Having bought a controlling stake in generics firm, Alvogen in 2015, Temasek alongside CVC have asked investment bank Jefferies to now find a buyer for the groups Central and Eastern European business.

 

Estimated to be worth around $1 billion, it is the first move the companies are making to exit from the firm known for its drugs against cancer, heart disease and liver disease.

 

Although it is too early to say which businesses have shown interest, a source for Alvogen was quoted as saying:  “The private equity owners of these companies have said that they want to use the platforms to build strong generics players, so most of the groups which showed an interest in Zentiva and Stada are expected to raise their hands for Alvogen’s Eastern European ops,”


Written by
Poppy covers a wide range of topics at Billionaire, having spent the past 13 years at companies including Singapore Tatler, Her World Plus and Harpers Bazaar UK. She has a passion for fashion, jewellery and travel as well as an avaricious fascination with crime novels. Follow her at poppypskinner on Instagram. 

End of content

No more pages to load

We have detected an active ad-blocker. Please consider whitelisting this website, to support our efforts in bringing you content.

Subscribe to Our Newsletter: